| European Case Law Identifier: | ECLI:EP:BA:2011:T152510.20110920 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 20 September 2011 | ||||||||
| Case number: | T 1525/10 | ||||||||
| Application number: | 97944240.7 | ||||||||
| IPC class: | A61K 9/20 A61K 31/19 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | C | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Pharmaceutical compositions for sustained release of the HMG-CoA reductase inhibitor fluvastatin | ||||||||
| Applicant name: | Novartis AG Novartis Pharma GmbH |
||||||||
| Opponent name: | Ratiopharm GmbH Actavis UK Ltd Actavis GmbH Mylan S.A.S. |
||||||||
| Board: | 3.3.02 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Main request and auxiliary request I - clarity (no): parameter and method for measuring it not clearly defined Auxiliary request I - Article 123(2) EPC (no): unallowable generalisation Auxiliary request II - admission (no): request withdrawn in first instance proceedings |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t101525eu1.html
Date retrieved: 17 May 2021